Gilead Sciences, Inc. (ETR:GIS)
96.10
+1.53 (1.62%)
Sep 18, 2025, 5:35 PM CET
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.08B USD in the quarter ending June 30, 2025, with 1.84% growth. This brings the company's revenue in the last twelve months to $28.86B, up 3.81% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.86B
Revenue Growth
+3.81%
P/S Ratio
4.78
Revenue / Employee
$1.64M
Employees
17,600
Market Cap
117.55B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Gilead Sciences News
- 11 hours ago - May 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq
- 1 day ago - Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management - Wallstreet:Online
- 1 day ago - Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management - GlobeNewsWire
- 1 day ago - GILD Partners with Nurix for Potential IRAK4 Protein Degrader - GuruFocus
- 2 days ago - Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus
- 2 days ago - QQQM, GOOGL, ADBE, GILD: Large Inflows Detected at ETF - Nasdaq
- 2 days ago - GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News - GuruFocus
- 3 days ago - Validea Detailed Fundamental Analysis - GILD - Nasdaq